RADIENT PHARMACEUTICALS — Amdl — Investor Presentation (July 2008)
25 slides from RADIENT PHARMACEUTICALS's investor presentation, Jul 3, 2008
Slide 1: AMDL, Inc. Investor Presentation
1 1 AMDL, INC. Investor Presentation July 3, 2008 Gary Dreher, CEO & President Doug MacLellan, Board Member
Slide 2: Disclosure Statement
2 Disclosure Statement Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward- looking statements under securities law. These statements involve a number of
Slide 3: AMDL Overview
3 3 Founded in 1987, Tustin, California-based AMDL Inc. is one of the fastest growing, vertically-integrated specialty pharmaceutical companies on the market. In combination with its Chinese subsidiary, Jade Pharmaceutical Inc. ("JPI"), the Company engages in the R&D, manufacturing, licensing, & app
Slide 4: Mission Statement
Mission Statement Establish the Company as one of the 10 major pharmaceutical companies in China. Increase in sales goal of 100% year over year from 2007 through 2009. Furthering the process of obtaining regulatory approvals for key products in diagnostic and pharmaceutical markets. Continue to take
Slide 5: Management Team
5 5 President, CEO, & AMDL Board Member: Mr. Gary L. Dreher is a seasoned bio-pharmaceutical executive with over 30 years of industry experience. (Tustin) Team Leader. Executive Director, Jade Pharmaceutical: Mr. Frank Zheng holds 22 years of China pharmaceutical business experience. (China) Head of
Slide 6: Board of Directors
6 6 Chairman: Bill Thompson, III, M.D., J.D., has extensive pharmaceutical patent experience ( Independent) Director/Audit & Governance Committee Chairman: Mr. Douglas MacLellan is an international business executive with 24 years of China business with 10 of those focused on the pharmaceutical indu
Slide 7: Positioned for Rapid Growth
Positioned for Rapid Growth 7 7 Tustin, CA Headquarters Chinese Facility 1 GMP Certified Facility
Slide 8: Jade Pharmaceuticals
8 Jade Pharmaceuticals Jade Pharmaceuticals Jade Pharmaceuticals Jade Pharmaceuticals currently manufactures and markets 48 products in China. 24 JJB branded generic drugs 24 YYB traditional Chinese medicines Substantial distribution network of 118 distributors. 51 JJB distributors 67 YYB distributo
Slide 9: Diversified Product Portfolio
Diversified Product Portfolio 9
Slide 10: Rapid Growth in Chinese Market for Health Products
10 Rapid Growth in Chinese Market for Health Products China's GDP growing at 8-10% annually. China's pharmaceuticals market is forecast to become the world's fifth largest by 2010 - and the largest by 2050. 2050. 2050. 2050. 2050. 2050. 2050. 2050. (1) Source: IMS Health Access (2) Source: Pricewate
Slide 11: DR-70 Cancer Test
11 The DR-70 ELISA test is used to monitor fibrin degradation products (FDP); it is currently being reviewed by the FDA. DR-70 is a standardized ELISA test to monitor the presence of colorectal cancer (CRC). CRC is the 3rd most common cancer worldwide & 2nd most common form of cancer in the U.S. CRC
Slide 12: DR-70 Regulatory Approvals
12 12 Approved in Canada for Lung Cancer Detection. Approved in Taiwan as a General Cancer Screen. Korean approval is for importation and sales as a General Cancer Screen. Approval in China (SFDA) is possible in 2010. FDA approval submission is for the monitoring of colon cancer patients. Has the CE
Slide 13: CIT Cancer Vaccine
13 13 A US patented technology (patent issued May 25, 2004). Shown to be effective in reprogramming a cancer patient's immune system to target and destroy cancer cells. CIT vaccine intended to protect patients known to be at risk because of family history for certain types of cancer. Phase I trials
Slide 14: Goodnak Anti-Aging Treatment
14 Goodnak Human Placental Histosolution has been shown to give skin a youthful appearance by increasing cell renewal and smoothing fine lines. Sales for the new anti-aging capsules & lotions products are expected in third quarter 2008. These new non-injectables complement the original Goodnak. AMDL
Slide 15: MyGene HPV Test Kit
15 MyGene HPV Test Kit Obtained sublicense agreement from MyGene International for HPV test in: ^ China ^ Thailand ^ Taiwan ^Cambodia ^ Singapore ^ Vietnam ^ Malaysia Estimated HPV tests completed in China alone equal: 2009 16 million 2025 25 million HPV testing is a $250 million worldwide market (M
Slide 16: Docetaxel
16 16 Chemotherapy treatment approved for use for 5 cancers. Breast Lung Prostate Gastric Head & Neck AMDL anticipates approval of this drug by the SFDA in 2008 because Docetaxel has been approved in the United States. Marketed under the name Taxotere by Sanofi Aventis. Docetaxel
Slide 17: Top 5 Selling Products (by JPI in 2008)
17 17 Human Placenta Tissue Injections (Goodnak(r)) 30.55% Domperidone 28.58% Calcium Hydrogen Phosphate and Lysine Tablets 9.01% Glucose Solutions 8.55% Levofloxacin Lactate and Sodium Chloride Injection 5.53% Top 5 Selling Products (by JPI in 2008)
Slide 18: China Distribution Channels
18 18 Total of 75 in house salespeople 300+ third-party, independent representatives in 36 key markets and substantial distribution network of 118 distributors AMDL anticipates expansion into additional 36 key cities in the next 12 months Ultimate goal of penetrating all 168 key cities within next 4
Slide 19: Income Statement
19 Income Statement Income Statement (In millions) Q1 2008 Q4 2007 Q3 2007 Q2 2007 Q1 2007 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) Revenue $ 3.59 $ 5.36 $ 5.81 $ 2.41 $ 1.42 Cost of Revenue, Total 1.82 2.71 2.23 1.26 0.70 Gross Profit 1.77 2.65 3.58 1.15 0.72 Selling/General/Admi
Slide 20: Balance Sheet
20 Balance Sheet (In millions) Q1 2008 Q4 2007 Q3 2007 Q2 2007 Q1 2007 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) Cash and Short Term Investments $ 3.57 $ 6.16 $ 1.23 $ 3.26 $ 0.47 Total Receivables, Net 3.97 2.96 3.06 1.34 1.28 Total Inventory 0.92 0.92 0.84 0.58 0.64 Prepaid Expen
Slide 21: Guidance
21 Guidance Significant increase in revenues anticipated during 2008. (in thousands) Quarter 2- $ 6,327 Quarter 3- $13,117 Quarter 4- $15,726 Total- $35,170 AMDL anticipates record net income of $11,030,000 before currency adjustments for 2008. Increase in revenues as a result of the new distributio
Slide 22: Projected Performance
22 Projected Performance 2008 Forecast (in thousands) Q1 Actual Q2 (Estimate) Q3 (Estimate) Q4 (Estimate) Total (Estimate) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) Revenue $ 3,588 $ 6,327 $ 13,117 $ 15,726 $ 38,758 Cost of Sales (1,817) (2,967) (5,900) (6,698) (17,382) 1,771 3,360
Slide 23: Peer Comparison & Valuation
23 Peer Comparison & Valuation Market Cap (M) Share Price** Price to Cash P/E (TTM) Price to Sales Sales Growth (MRQ) vs.1 year ago Sales Growth (MRQ) vs.1 year ago Gross Margin Net Profit Margin AMDL $45 $3.04 - 6.56* 1.61* 151.97 151.97 53.28 33.00* CMED $1,119 $43.28 24.88 25.88 8.90 74.26 74.26
Slide 24: Financial View
24 24 Source: Big Charts Financial View Stock Price (6/27/2008) $3.03 2007 Revenue $15.00 Million Market Cap 47.74 Million 2007 Gross Profit $8.1 Million 52 Week High $5.10 Q1 2008 Revenue $3.59 Million 52 Week Low $2.25 Q1 2008 Gross Profit $1.77 Million Average Volume 39,053 Q1 2008 sales growth v
Slide 25: Highlights
25 25 Increase in sales goal of 100% year over year from 2007 through 2009 years. Revenue for 2008 expected to be $38 million with net income of $11 million before currency exchange. New Goodnak products will complement original injectable formula, these products have high margins of up to 60%. Rece